| Company Name: | Allion Healthcare, Incorporated | | Ticker Symbol: | ALLI | | | WWW Address: | www.allionhealthcare.com |
| CEO: | Michael P. Moran | | No. of Employees: | 249 |
| Common Issue Type: | CS | | Business Description: | The Company is a national provider of specialty pharmacy and disease management services focused on HIV/AIDS patients, as well as specialized biopharmaceutical medications and services for chronically ill patients.
|
| | | Industry Information: | HEALTH SERVICES - Specialized Health Services [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 6.59 |  0.0 | - | - | | 6.59 | 6.59 | - |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 189.1 | 28.7 | 1.38 | 0.34 | 0.00 | 13.7 | 0.0 | 7.74 - 3.67 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 6.59 | $ | | PE Ratio - LTM | 13.7 | |
| Market Capitalisation | 189.1 | mil |
| Latest Shares Outstanding | 28.7 | mil |
| Earnings pS (EPS) | 0.34 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 1,368,169 | $ |
| Effective Tax Rate | 41.1 | % |
| Float | 20.7 | mil |
| Float as % of Shares Outstanding | 72.2 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 10.00 | % |
| Research & Devlopment (R&D) as % of Revenue | 0.00 | % |
| Gross Profit Margin | 18.6 | % |
| EBITDA Margin | 8.6 | % |
| Pre-Tax Profit Margin | 5.9 | % |
| Assets Turnover | 1.3 | % |
| Return on Assets (ROA) | 4.0 | % |
| Return on Equity (ROE) | 6.7 | % |
| Return on Capital Invested (ROCI) | 4.8 | % |
| Current Ratio | 2.7 | |
| Leverage Ratio (Assets/Equity) | 1.7 | |
| Interest Cover | 7.1 | |
| Total Debt/Equity (Gearing Ratio) | 0.41 | |
| LT Debt/Total Capital | 28.0 | % |
| Working Capital pS | 1.96 | $ |
| Cash pS | 0.73 | $ |
| Book-Value pS | 6.73 | $ |
| Tangible Book-Value pS | -1.17 | $ |
| Cash Flow pS | 0.67 | $ |
| Free Cash Flow pS | 1.84 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.98 | |
| Price/Tangible Book Ratio | -5.64 | |
| Price/Cash Flow | 9.9 | |
| Price/Free Cash Flow | 3.6 | |
| P/E as % of Industry Group | 45.0 | % |
| P/E as % of Sector Segment | 35.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.0 | 104 | 228 | |
| 4 Weeks | 6.60 | 6.55 | 6.55 | 0.6 | 104 | 573 | 10,308 |
| 13 Weeks | 6.60 | 6.42 | 6.44 | 2.3 | 101 | 1,210 | 73,803 |
| 26 Weeks | 7.74 | 4.75 | 6.86 | -3.9 | 86 | 2,159 | 269,935 |
| 52 Weeks | 7.74 | 3.67 | 4.28 | 54.0 | 117 | 1,522 | 382,137 |
| YTD | 6.60 | 6.56 | - | 0.5 | 103 | 395 | 5,536 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 6.59 | 6.59 | 6.54 | 6.48 | 6.19 | 1.38 | 1.33 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 44.31 | 93.4 | 23.59 |
| Income | 0.00 | 0.0 | 39.43 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 3.53 | NA | -74.85 |
| R&D | 0.00 | NA | 0.00 |
| Normalized Inc. | 0.00 | NA | 49.84 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 22.9 | 12.2 | 38.1 |
| Earnings % | 123.3 | 15.4 | 130.7 |
| EPS % | 61.9 | 0.0 | 78.9 |
| EPS $ | 0.13 | 0.00 | 0.15 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 17.50 |
| Current Ratio | 2.5 |
| Quick Ratio (Acid Test) | 2.1 |
| Liquidity Ratio (Cash) | 0.61 |
| Receivables Turnover | 10.8 |
| Average Collection Period | 33 |
| Working Capital/Equity | 28.0 |
| Working Capital pS | 1.83 |
| Cash-Flow pS | 0.51 |
| Free Cash-Flow pS | 0.12 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.86 |
| Financial Leverage Ratio (Assets/Equity) | 1.6 |
| Debt Ratio | 37.5 |
| Total Debt/Equity (Gearing Ratio) | 0.33 |
| LT Debt/Equity | 0.32 |
| LT Debt/Capital Invested | 31.7 |
| LT Debt/Total Liabilities | 52.8 |
| Interest Cover | 5.3 |
| Interest/Capital Invested | 1.22 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 5.57 |
| Tobin's Q Ratio | 0.70 |
| Current P/E Ratio - LTM | 13.70 |
| Enterprise Value (EV)/EBITDA | 10.70 |
| Enterprise Value (EV)/Free Cash Flow | 158.79 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -5.64 |
| Price/Book Ratio - LTM | 0.98 |
| Price/Cash Flow Ratio | 9.9 |
| Price/Free Cash Flow Ratio - LTM | 3.6 |
| Price/Sales Ratio | 0.48 |
| P/E Ratio (1 month ago) - LTM | 13.7 |
| P/E Ratio (26 weeks ago) - LTM | 14.3 |
| P/E Ratio (52 weeks ago) - LTM | 21.4 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 45.0 |
| P/E as % of Sector Segment | 35.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 13.3 |
| PER SHARE FIGURES |
| LT Debt pS | 2.07 |
| Current Liabilities pS | 1.19 |
| Tangible Book Value pS - LTM | -1.17 |
| Book Value pS - LTM | 6.73 |
| Capital Invested pS | 7.77 |
| Cash pS - LTM | 0.73 |
| Cash Flow pS - LTM | 0.67 |
| Free Cash Flow pS - LTM | 1.84 |
| Earnings pS (EPS) | 0.34 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 0.94 |
| Free Cash Flow Margin 5YEAR AVG | -8.23 |
| Net Profit Margin | 2.2 |
| Net Profit Margin - 5YEAR AVRG. | 1.2 |
| Equity Productivity | 2.01 |
| Return on Equity (ROE) | 4.4 |
| Return on Equity (ROE) - 5YEAR AVRG. | 2.6 |
| Capital Invested Productivity | 1.53 |
| Return on Capital Invested (ROCI) | 3.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 2.3 |
| Assets Productivity | 1.70 |
| Return on Assets (ROA) | 2.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | 1.9 |
| Gross Profit Margin | 18.6 |
| Gross Profit Margin - 5YEAR AVRG. | 16.7 |
| EBITDA Margin - LTM | 8.6 |
| EBIT Margin - LTM | 6.9 |
| Pre-Tax Profit Margin | 3.7 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 2.1 |
| Effective Tax Rate | 41.1 |
| Effective Tax Rate - 5YEAR AVRG. | 28.3 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 61 |
| Revenue per Employee | 1,368,169 |
| Net Income per Employee | 30,201 |
| Average Collection Period | 47 |
| Receivables Turnover | 10.8 |
| Day's Inventory Turnover Ratio | 14 |
| Inventory Turnover | 26.5 |
| Inventory/Sales | 3.8 |
| Accounts Payble/Sales | 7.23 |
| Assets/Revenue | 0.59 |
| Net Working Capital Turnover | 7.18 |
| Fixed Assets Turnover | 1.77 |
| Total Assets Turnover | 1.7 |
| Revenue per $ Cash | 18.53 |
| Revenue per $ Plant | 206.85 |
| Revenue per $ Common Equity | 2.01 |
| Revenue per $ Capital Invested | 1.53 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 10.4 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 12.4 |
| Research & Devlopment (R&D) as % of Revenue | 0.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 0.0 |
|
|  
|
| |
 |  |
